scholarly journals Distortion of Capillary Serum Protein Electrophoresis Pattern May Indicate Monoclonal Gammopathy of Undetermined Significance but Not Multiple Myeloma

2018 ◽  
Vol 150 (suppl_1) ◽  
pp. S98-S98
Author(s):  
Christine Liang ◽  
Lin Zhang ◽  
Amitava Dasgupta ◽  
Md Wahed
Keyword(s):  
Multiple Myeloma ◽  
Serum Protein ◽  
Monoclonal Gammopathy ◽  
Protein Electrophoresis ◽  
Serum Protein Electrophoresis ◽  
Undetermined Significance ◽  
Electrophoresis Pattern

Pyoderma Gangrenosum and IgA Myeloma

1997 ◽  
Vol 2 (2) ◽  
pp. 100-103 ◽  
Author(s):  
J. Mark Jackson ◽  
Jeffrey P. Collen
Keyword(s):  
Multiple Myeloma ◽  
Serum Protein ◽  
Pyoderma Gangrenosum ◽  
Monoclonal Gammopathy ◽  
Systemic Disease ◽  
Protein Electrophoresis ◽  
Serum Protein Electrophoresis ◽  
Potential Association ◽  
Uncommon Condition

Background: Pyoderma gangrenosum (PG) is an uncommon condition that is associated with a systemic disease in 50% of patients. The condition may be associated with a monoclonal gammopathy, usually of the IgA type. It is rare for PG to be associated with multiple myeloma. Observations: We report the case of an 83-year-old man with PG associated with an IgA myeloma. The myeloma was discovered after the diagnosis of PG had been made. This is the 22nd case of multiple myeloma associated with PG, and only the 14th case of PG with an IgA myeloma. Conclusions: We should be aware of the potential association of multiple myeloma with PG, and consider doing a serum protein electrophoresis in the evaluation of patients with PG.

scholarly journals Superiority of Serum Immunofixation Electrophoresis over Serum Protein Electrophoresis in the Diagnosis of Multiple Myeloma

2018 ◽  
Vol 36 (3) ◽  
pp. 95-100
Author(s):  
Mohammed Mosleh Uddin ◽  
Md Mizanur Rahman ◽  
Syeda Adib Sultana ◽  
Debashish Saha
Keyword(s):  
Multiple Myeloma ◽  
Serum Protein ◽  
Monoclonal Gammopathy ◽  
Plasma Cells ◽  
Cell Lineage ◽  
Armed Forces ◽  
Protein Electrophoresis ◽  
Serum Protein Electrophoresis ◽  
Suspected Case ◽  
Immunofixation Electrophoresis

Background: Multiple Myeloma (MM) is a neoplasm of B cell lineage characterized by excessive proliferation of abnormal plasma cells, secreting abnormal immunoglobulin causing monoclonal gammopathy which can be detected by the presence of M protein in serum and urine electrophoresis.Aim: Present study is aimed to detect and quantify monoclonal gamma globulins by SPEP and IFE in suspected case of MM and other plasma cell dyscrasias and also to find out the discrepant findings between SPEP and IFE.Methods: A retrospective observational study was carried out on clinically highly suspected cases of Multiple Myeloma (MM) presenting with backache, asthenia and generalized weakness at Armed forces Institute of Pathology(AFIP), Dhaka cantonment from January 2015 to July 2016. A total of 140 blood samples were collected and subjected to serum protein electrophoresis (SPEP) and Immunofixation electrophoresis (IFE). IFE identifies the type of heavy (IgG, IgM or IgA) and light chain (either kappa or lambda in suspected cases of MMResults: Out of 140 cases, SPEP identified monoclonal band in 62 cases and either non-specific findings or polyclonal band in 78 cases. At the same time immunofixation electrophoresis (IFE) which was done on all samples detected another 14 cases of M-band in addition to earlier 62 cases of monoclonal gammopathy by SPEP. Among 140 cases, SPEP detected M-band in 62 cases, whereas IFE identified monoclonal band in 76 cases. So in the remaining 14 cases (10%) small sharp spikes of monoclonal band was found only by IFE whereas SPEP failed to detect those 14 cases.Conclusion: SPEP is an easy to perform laboratory test which can be used for detection and quantification of monoclonal gammopathy but there is some limitation in detecting monoclonal band by SPEP. IFE is more sensitive to detect the monoclonal band than SPEP. So both SPEP and IFE should be done simultaneously for precise diagnosis of MM and related disorders.J Bangladesh Coll Phys Surg 2018; 36(3): 95-100

Feline Lymphoplasmacytic Stomatitis Associated with Monoclonal Gammopathy and Bence-Jones Proteinuria

1994 ◽  
Vol 11 (1) ◽  
pp. 25-27 ◽  
Author(s):  
Kenneth F. Lyon
Keyword(s):  
Multiple Myeloma ◽  
Oral Cavity ◽  
Serum Protein ◽  
Monoclonal Gammopathy ◽  
Alkylating Agent ◽  
Protein Electrophoresis ◽  
M Protein ◽  
Monoclonal Immunoglobulin ◽  
Urine Protein ◽  
Bence Jones Proteinuria

Lymphoplasmacytic stomatitis and gingivitis was diagnosed in an 8-year old female domestic shorthair. The cat had evidence of severe generalized inflammation of the oral cavity. Biopsy samples were evaluated and displayed a lichenoid, interface stomatitis which was predominantly lymphoplasmacytic. Serum protein electrophoresis confirmed a monoclonal gammopathy. Urine protein electrophoresis confirmed Bence-Jones proteinuria. Protein electrophoresis was used to diagnose monoclonal gammopathy (the production of a monoclonal immunoglobulin, or paraprotein, which is associated with a characteristic “M” protein spike on serum electrophoresis). Diseases associated with monoclonal gammopathy are similar in the dog and cat. Alkylating agent chemotherapy is used to rapidly reduce paraprotein concentrations in multiple myeloma. Multiple myeloma is the most common disorder associated with monoclonal gammopathy. This condition is less common in the cat, compared to the dog. This report examines the diagnosis and treatment of multiple myeloma in a cat presenting with severe stomatitis.

The Biologic and Analytic Variability of Serum Protein Electrophoresis M-Spike, Nephelometric Ig Quantitation, Serum FLC Quantitation, and Urine M-Spike in Monoclonal Gammopathies.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 1803-1803
Author(s):  
Melissa Snyder ◽  
Angela Dispenzieri ◽  
S.Vincent Rajkumar ◽  
Robert Kyle ◽  
Joanne Benson ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Serum Protein ◽  
Protein Electrophoresis ◽  
Serum Protein Electrophoresis ◽  
Monoclonal Gammopathies ◽  
Number Of Patients ◽  
Measurable Disease ◽  
M Spike ◽  
Serial Samples ◽  
Serum And Urine

Abstract Abstract 1803 Poster Board I-829 Background Plasma cell proliferative disorders are monitored by a variety of methods. Serum protein electrophoresis (SPEP) and/or urine PEP M-spike quantitation are commonly assessed in patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and multiple myeloma (MM) to determine disease progression, response, or relapse. Serum immunoglobin (Ig) concentrations can be quantitated when the M-spike is large or if the migration is obscured within the SPEP beta fraction. Serum FLC quantitation provides a rapid indicator of response, will detect the rare occurrence of FLC escape, and will allow disease monitoring in the absence of a measurable serum or urine M-spike. The International Myeloma Working Group (IMWG) has recommended that the serum and urine M-spike should be used to monitor disease, and that FLC quantitation should be used only if there is no measurable disease by electrophoresis and if the monoclonal FLC concentration is greater than 10 mg/dL in the context of an abnormal FLC K/L ratio. We have studied serial samples in clinically stable patients in order to assess the total variability (analytic and biologic) of these assays and to confirm the IMWG recent recommendations. Methods Serial data from stable MGUS patients (n=35) were identified by the availability of all 3 serum test results (M-spike, Ig, FLC) in at least 4 serial samples that were obtained 9 months to 5 years apart and whose serum M-spikes varied by less than 25%. For MM (n=60) and SMM (n=48) the samples were within 9-15 months and serum M-spikes varied by less than 0.5 g/dL. Among the 60 MM, 48 SMM, and 35 MGUS patients, there were 23, 41, and 18 patients with measurable disease by serum M-spike (i.e. M-spike >1 g/dL); 19, 10, and 10 patients with an evaluable FLC (i.e. monoclonal FLC > 10 mg/dL and an abnormal FLC ratio); and 5, 5, and 1 patient with an evaluable urine (i.e. M-spike > 200mg/24 hr). The FLC data was analyzed as the involved FLC concentration (iFLC), the difference between the involved and uninvolved FLC concentration (dFLC), and the FLC K/L ratio (rFLC). The coefficients of variability (CV) were determined for each methodology in each patient sample set, and the average CVs were determined. Igs were quantitated by immunonephelometry using a Siemens BNII and Siemens reagent sets; kappa and lambda FLC were quantitated using a Siemens BNII and Freelite reagent sets from The Binding Site; M-spikes were quantitated using Helena SPIFE SPE and reagent sets. Results The CVs for the Ig quantitation, SPEP M-spike, FLC quantitation, and urine M-spike in each of the patient groups are listed in the table: Our laboratory's interassay analytic CV for replicate samples are 4-5% for Ig quantitation, 6-8% for SPEP M-spikes, 6-7% for FLC quantitation, and 5-7% for urine M-spikes. The analytic CVs of the methods are similar, but the total (analytic + biologic) CVs are very different. The samples have been selected by restricting the variability of serum M-spike values; when we apply the same criteria to the IgG quantitation, the IgG total CV comes closer to the serum M-spike CVs. The remaining differences, however, may be due to biologic variability contributed by polyclonal Ig. The total CV for iFLC is similar to the urine M-spike CV and suggests a previously unrecognized large biologic CV for serum FLC. The iFLC and dFLC CVs were comparable but were smaller than the rFLC CV. Conclusion The variability of the serum and urine M-spike, Ig, and FLC measurements confirm the IMWG recommendations for patient monitoring. If a patient has a measurable M-spike >1 g/dL, then the serum M-spike should be followed. If there is no measurable disease, then the iFLC can be monitored, provided that the rFLC is abnormal and the iFLC concentration is >10 mg/dL. Although the number of patients with evaluable urine M-spikes in this study is small, larger studies may confirm the utility of serum FLC compared to urine M-spike for monitoring patients with monoclonal gammopathies. Disclosures No relevant conflicts of interest to declare.

scholarly journals ELEKTROFORESIS PROTEIN SERUM PASIEN DENGAN KADAR PROTEIN NORMAL

2018 ◽  
Vol 15 (3) ◽  
pp. 87
Author(s):  
Tiene Rostini ◽  
Coriejati Rita
Keyword(s):  
Serum Protein ◽  
Total Protein ◽  
Protein Level ◽  
Protein Electrophoresis ◽  
Serum Protein Electrophoresis ◽  
Total Protein Level ◽  
Normal Limits ◽  
Nephritic Syndrome ◽  
Serum Protein Level ◽  
Electrophoresis Pattern

Serum protein electrophoresis pattern can assist in diagnosis of liver disease, hematological disorders, renal disorders andgastrointestinal disease. Measurement of total protein level in the serum cannot detect any disorders in patient with normal limit ofserum total protein level. The aim of this study; was to evaluate the serum protein electrophoresis pattern in patient with normal limitsof serum protein level. This research was carried out by descriptive retrospective study using the electrophoresis data from patients’medical record at the Clinical Pathology Department, Dr. Hasan Sadikin General Hospital Bandung. The data of serum electrophoresis (bySebia gel electrophoresis) were grouped based on disease or disorders, and confirmed with the diagnosis derived from patient’s medicalrecord. Inclusion criteria of samples if ; the electrophoresis data were available, serum total protein level within normal limits (6.4–8.3mg/dL), and the data of electrophoresis taken from medical record were taken from August 2006 until August 2008. The result foundso far was, there were 240 data of electrophoresis from patients with serum protein level within normal limits (6.4–8.3 mg/dL). theinterpretation of electrophoresis consist of: 1) inflammation (149 patients; 62.2% ; sensitivity 83.7%, specificity 86,5%) 2) Cirrhosis(46 patients ; 19.2% ; sensitivity 87.5% ; specificity 88.4%) 3) Nephritic syndrome (15 patients ; 6.2%; sensitivity 53%; specificity96.9% 4) Monoclonal gammophaty (15 patients(6.2% ; sensitivity 80% ; specificity 98.7%) 5) Normal pattern in 15 patient (6.2%).This study found abnormal serum protein electrophoresis pattern in the condition of inflammation, Cirrhosis, Nephritic Syndrome, andMonoclonal gammophaty. It can be concluded that many disorders could be detected in patient with serum protein level within normallimits such as: inflammation, cirrhosis, nephritis syndrome and monoclonal gammophaty by abnormal electrophoresis pattern

scholarly journals Usefulness of serum globulin levels for discriminating patients with monoclonal gammopathies/ paraproteinemias

Biomedicine ◽  
2021 ◽  
Vol 41 (1) ◽  
pp. 31-35
Author(s):  
Neelam M Pawar ◽  
Anupama Hegde
Keyword(s):  
Serum Protein ◽  
Total Protein ◽  
Monoclonal Gammopathy ◽  
Protein Electrophoresis ◽  
Serum Protein Electrophoresis ◽  
Serum Globulin ◽  
Protein Ratio ◽  
Monoclonal Gammopathies ◽  
Median Serum ◽  
Control Study

Introduction and Aim: The confirmatory step in diagnosis of monoclonal gammopathies is bone marrow biopsy and presence of M-protein in serum protein electrophoresis. These tests are relatively expensive & invasive for screening and unavailable in low resource settings. Increased levels of serum globulin are clue to the diagnosis of monoclonal gammopathy. The aim of this study was to assess the relevance of serum globulin levels in discriminating between patients with & without monoclonal gammopathies/ paraproteinemia. Materials and Methods: We retrospectively reviewed serum protein electrophoresis (SPE) and related investigations of patients suspected of monoclonal gammopathy. Reports with an M-band were considered as paraproteinemias, and those without as controls. ROC for sensitivities & specificities for serum globulin levels were computed. Results: For the case-control study, median serum globulin values in cases were 4.4 (3.5-6.3) g/dL in males and 3.65 (3.33-5.0) g/dL in females. They were significantly higher than those with normal SPE pattern, with a p <0.001. A cut-off value of 3.25 g/dL of globulin could distinguish between paraproteinemias and controls with a sensitivity of 82.1% and specificity of 85.4% in males; a sensitivity of 79.2%, a specificity of 76.7% for females. At a cut-off value of 3.4 g/dL, sensitivity was 77% and specificity 92.7% for males; sensitivity was 75% and specificity 83.7% for females. Alternatively, a cut-off value of 0.458 of globulin/total protein ratio could distinguish at a best sensitivity & specificity of 80% and 89% in males; 83.3% and 83.7% in females. Conclusion: Serum globulin values and globulin/total protein ratio can reliably differentiate patients with paraproteinemias.

Test Utilization of Serum Protein Electrophoresis and Immunofixation Electrophoresis

2019 ◽  
Vol 152 (Supplement_1) ◽  
pp. S146-S147
Author(s):  
Roula Katerji ◽  
Tamera Paczos ◽  
Li Liu
Keyword(s):  
Multiple Myeloma ◽  
Serum Protein ◽  
Active Treatment ◽  
Cost Effective ◽  
Protein Electrophoresis ◽  
Serum Protein Electrophoresis ◽  
Efficient Test ◽  
Testing Frequency ◽  
Immunofixation Electrophoresis ◽  
Changes Over Time

Abstract Objectives Serum protein electrophoresis (SPE) and immunofixation electrophoresis (IFE) are commonly used to screen and monitor monoclonal gammopathies. Currently, there are no consensus guidelines on optimal testing frequency leading to overutilization. Here we examined the testing frequencies of SPE and IFE in our institution to provide an evidence-based perspective on efficient test utilization. Methods We retrospectively reviewed all SPE and IFE tests performed in 2018. Ordering patterns and testing frequencies were analyzed. In cases with more than monthly repeats, electronic medical records were reviewed to follow the result changes over time. Results There were 10,054 SPE and 4,248 IFE orders in 2018. The 4,248 IFE cases represented 2,439 patients, among whom 104 patients (4.3%) had IFE repeated more frequently than every 2 months and 50 patients (2%) more frequently than monthly. The 10,054 SPE cases represented 5,472 patients; 127 patients (2.3%) had SPE performed more than 12 times. Rare cases (0.1%) had SPE and IFE repeated every 1 to 2 weeks. Most IFE tests were ordered together with SPE (89% of all IFE orders), among which 28% of cases had normal SPE findings. Among the cases with more than monthly SPE and IFE tests, IFE results showed meaningful interpretation changes in a minimum period of 2 to 3 months; 35% cases had no IFE interpretation changes throughout the year. In contrast, during active treatment period of multiple myeloma, SPE detected paraprotein level change weekly. Conclusion IFE is overutilized and monthly monitoring does not add value even during active treatment of multiple myeloma. Our results support the need for the development of testing frequency guidelines to avoid overutilization and provide more cost-effective patient care.

Sign in / Sign up

Export Citation Format

Share Document